Raras
Buscar doenças, sintomas, genes...
Imunodeficiência combinada grave T-B+
ORPHA:317416CID-10 · D81.2CID-11 · 4A01.10DOENÇA RARA

A imunodeficiência combinada grave TB+ (SCID) é um grupo de distúrbios raros de imunodeficiência primária monogênica caracterizados pela falta de linfócitos T periféricos funcionais com presença de linfócitos B, resultando em infecções respiratórias virais, bacterianas ou fúngicas graves de início precoce, diarréia e retardo de crescimento.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A imunodeficiência combinada grave TB+ (SCID) é um grupo de distúrbios raros de imunodeficiência primária monogênica caracterizados pela falta de linfócitos T periféricos funcionais com presença de linfócitos B, resultando em infecções respiratórias virais, bacterianas ou fúngicas graves de início precoce, diarréia e retardo de crescimento.

Publicações científicas
34 artigos
Último publicado: 2025 Nov 25
Medicamentos
1 registrados
PALIFERMIN

Tem tratamento?

1 medicamento registrado
Ver detalhes, fases e interações →
PALIFERMIN
🏥
SUS: Cobertura mínimaScore: 5%
Triagem neonatal (Fase 4)CID-10: D81.2
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🩸
Sangue
16 sintomas
🛡️
Imunológico
14 sintomas
🫃
Digestivo
12 sintomas
🫁
Pulmão
11 sintomas
🧬
Pele e cabelo
8 sintomas
📏
Crescimento
5 sintomas

+ 61 sintomas em outras categorias

Características mais comuns

Linfopenia
Hepatite
Febre
Formação recorrente de abscesso
Anorexia
Linfocitose
133sintomas
Sem dados (133)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 133 características clínicas mais associadas, ordenadas por frequência.

LinfopeniaLymphopenia
HepatiteHepatitis
FebreFever
Formação recorrente de abscessoRecurrent abscess formation
Anorexia

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico34PubMed
Últimos 10 anos9publicações
Pico20193 papers
Linha do tempo
2025Hoje · 2026🧪 1997Primeiro ensaio clínico📈 2019Ano de pico
Publicações por ano (últimos 10 anos)

Triagem neonatal (Teste do Pezinho)

👶
Teste: TREC (T-cell Receptor Excision Circles)
Fase 4 do PNTNpending
Incidência no Brasil: 1:50.000

A triagem neonatal permite diagnóstico precoce e início imediato do tratamento.

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

9 genes identificados com associação a esta condição.

IL7RInterleukin-7 receptor subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP)

LOCALIZAÇÃO

Cell membraneSecreted

VIAS BIOLÓGICAS (1)
Clathrin-mediated endocytosis
MECANISMO DE DOENÇA

Immunodeficiency 104, severe combined

A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
89.7 TPM
Intestino delgado
57.7 TPM
Baço
51.2 TPM
Fibroblastos
32.7 TPM
Sangue
22.3 TPM
OUTRAS DOENÇAS (3)
immunodeficiency 104Omenn syndromeT-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency
HGNC:6024UniProt:P16871
PTPRCReceptor-type tyrosine-protein phosphatase CCandidate gene tested inAltamente restrito
FUNÇÃO

Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor (PubMed:35767951). Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity (By similarity). Interacts with CLEC10A at antigen pres

LOCALIZAÇÃO

Cell membraneMembrane raftSynapse

VIAS BIOLÓGICAS (3)
Phosphorylation of CD3 and TCR zeta chainsOther semaphorin interactionsNeutrophil degranulation
MECANISMO DE DOENÇA

Multiple sclerosis

A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
218.4 TPM
Baço
135.7 TPM
Linfócitos
109.4 TPM
Pulmão
63.7 TPM
Intestino delgado
28.2 TPM
OUTRAS DOENÇAS (2)
immunodeficiency 105T-B+ severe combined immunodeficiency due to CD45 deficiency
HGNC:9666UniProt:P08575
CD3DT-cell surface glycoprotein CD3 delta chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (6)
Translocation of ZAP-70 to Immunological synapseDownstream TCR signalingPhosphorylation of CD3 and TCR zeta chainsImmunoregulatory interactions between a Lymphoid and a non-Lymphoid cellClathrin-mediated endocytosis
MECANISMO DE DOENÇA

Immunodeficiency 19, severe combined

An autosomal recessive form of severe combined immunodeficiency characterized by onset in early infancy of recurrent bacterial, viral, and fungal infections. Patients usually have chronic diarrhea, recurrent respiratory infections, and failure to thrive. Immunologic work-up shows a T-cell negative, B-cell positive, NK-cell positive phenotype.

OUTRAS DOENÇAS (2)
immunodeficiency 19T-B+ severe combined immunodeficiency due to CD3delta/CD3epsilon/CD3zeta
HGNC:1673UniProt:P04234
CD247T-cell surface glycoprotein CD3 zeta chainDisease-causing germline mutation(s) inModerado
FUNÇÃO

Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (9)
Translocation of ZAP-70 to Immunological synapseDownstream TCR signalingPhosphorylation of CD3 and TCR zeta chainsImmunoregulatory interactions between a Lymphoid and a non-Lymphoid cellFCGR3A-mediated phagocytosis
MECANISMO DE DOENÇA

Immunodeficiency 25

An immunological deficiency characterized by T-cells impaired immune response to alloantigens, tetanus toxoid and mitogens.

OUTRAS DOENÇAS (4)
immunodeficiency 25rheumatoid factor-negative juvenile idiopathic arthritisT-B+ severe combined immunodeficiency due to CD3delta/CD3epsilon/CD3zetaoligoarticular juvenile idiopathic arthritis
HGNC:1677UniProt:P20963
CORO1ACoronin-1ADisease-causing germline mutation(s) inRestrito
FUNÇÃO

May be a crucial component of the cytoskeleton of highly motile cells, functioning both in the invagination of large pieces of plasma membrane, as well as in forming protrusions of the plasma membrane involved in cell locomotion. In mycobacteria-infected cells, its retention on the phagosomal membrane prevents fusion between phagosomes and lysosomes

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCytoplasm, cell cortexCytoplasmic vesicle, phagosome membrane

VIAS BIOLÓGICAS (1)
Prevention of phagosomal-lysosomal fusion
MECANISMO DE DOENÇA

Immunodeficiency 8 with lymphoproliferation

A disease of the immune system leading to recurrent infections, and characterized by CD4+ T-cells lymphopenia. Patients can develop B-cell lymphoproliferation associated with Epstein-Barr virus infection.

OUTRAS DOENÇAS (1)
severe combined immunodeficiency due to CORO1A deficiency
HGNC:2252UniProt:P31146
LATLinker for activation of T-cells family member 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Required for TCR (T-cell antigen receptor)- and pre-TCR-mediated signaling, both in mature T-cells and during their development (PubMed:23514740, PubMed:25907557). Involved in FCGR3 (low affinity immunoglobulin gamma Fc region receptor III)-mediated signaling in natural killer cells and FCER1 (high affinity immunoglobulin epsilon receptor)-mediated signaling in mast cells. Couples activation of these receptors and their associated kinases with distal intracellular events such as mobilization of

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Generation of second messenger moleculesGPVI-mediated activation cascade
MECANISMO DE DOENÇA

Immunodeficiency 52

An autosomal recessive primary immunodeficiency characterized by T-cell abnormalities, resulting in severe combined immunodeficiency, autoimmune disease, progressive lymphopenia and hypogammaglobulinemia, and lymphoproliferation with splenomegaly. Patients develop severe recurrent infections from infancy.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
62.6 TPM
Baço
51.9 TPM
Artéria coronária
49.8 TPM
Aorta
49.7 TPM
Cólon sigmoide
48.8 TPM
OUTRAS DOENÇAS (1)
severe combined immunodeficiency due to LAT deficiency
HGNC:18874UniProt:O43561
CD3ET-cell surface glycoprotein CD3 epsilon chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response (PubMed:15294938, PubMed:15546002, PubMed:2470098, PubMed:40592325, PubMed:8490660). When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z (PubMed:2470098, PubMed:40592325). All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (4)
Translocation of ZAP-70 to Immunological synapseDownstream TCR signalingPhosphorylation of CD3 and TCR zeta chainsImmunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
MECANISMO DE DOENÇA

Immunodeficiency 18

An autosomal recessive primary immunodeficiency characterized by onset in infancy or early childhood of recurrent infections. The severity is variable, encompassing both a mild immunodeficiency and severe combined immunodeficiency (SCID), resulting in early death without bone marrow transplantation in some patients. Immunologic work-up of the IMD18 SCID patients shows a T cell-negative, B cell-positive, natural killer (NK) cell-positive phenotype, whereas T-cell development is not impaired in the mild form of IMD18.

OUTRAS DOENÇAS (2)
immunodeficiency 18T-B+ severe combined immunodeficiency due to CD3delta/CD3epsilon/CD3zeta
HGNC:1674UniProt:P07766
JAK3Tyrosine-protein kinase JAK3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosph

LOCALIZAÇÃO

Endomembrane systemCytoplasm

VIAS BIOLÓGICAS (10)
RAF/MAP kinase cascadeInterleukin receptor SHC signalingInterleukin-2 signalingInterleukin-4 and Interleukin-13 signalingInterleukin-7 signaling
MECANISMO DE DOENÇA

Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative

A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
139.2 TPM
Baço
108.5 TPM
Linfócitos
42.0 TPM
Ovário
39.2 TPM
Pulmão
27.5 TPM
OUTRAS DOENÇAS (1)
T-B+ severe combined immunodeficiency due to JAK3 deficiency
HGNC:6193UniProt:P52333
IL2RGCytokine receptor common subunit gammaDisease-causing germline mutation(s) inDesconhecido
FUNÇÃO

Common subunit for the receptors for a variety of interleukins. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15 (PubMed:15123770)

LOCALIZAÇÃO

Cell membraneCell surface

VIAS BIOLÓGICAS (9)
RAF/MAP kinase cascadeInterleukin receptor SHC signalingInterleukin-2 signalingInterleukin-4 and Interleukin-13 signalingInterleukin-7 signaling
MECANISMO DE DOENÇA

Severe combined immunodeficiency X-linked T-cell-negative/B-cell-positive/NK-cell-negative

A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
410.7 TPM
Linfócitos
347.9 TPM
Baço
165.1 TPM
Intestino delgado
62.0 TPM
Pulmão
48.1 TPM
OUTRAS DOENÇAS (3)
T-B+ severe combined immunodeficiency due to gamma chain deficiencycombined immunodeficiency, X-linkedOmenn syndrome
HGNC:6010UniProt:P31785

Medicamentos e terapias

PALIFERMINPhase 1

Mecanismo: Fibroblast growth factor receptor 2 agonist

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

246 variantes patogênicas registradas no ClinVar.

🧬 IL7R: NM_002185.5(IL7R):c.46C>T (p.Gln16Ter) ()
🧬 IL7R: GRCh38/hg38 5p13.3-11(chr5:30831208-46273389)x3 ()
🧬 IL7R: NM_002185.5(IL7R):c.538-1_538delinsCA ()
🧬 IL7R: NM_002185.5(IL7R):c.226del (p.Ala76fs) ()
🧬 IL7R: NM_002185.5(IL7R):c.800+24A>T ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1,228 variantes classificadas pelo ClinVar.

123
123
982
Patogênica (10.0%)
VUS (10.0%)
Benigna (80.0%)
VARIANTES MAIS SIGNIFICATIVAS
JAK3: NM_000215.4(JAK3):c.853G>T (p.Glu285Ter) [Pathogenic]
JAK3: NM_000215.4(JAK3):c.1190G>T (p.Gly397Val) [Pathogenic]
JAK3: NM_000215.4(JAK3):c.98G>A (p.Arg33Gln) [Uncertain significance]
JAK3: NM_000215.4(JAK3):c.41G>A (p.Arg14His) [Uncertain significance]
JAK3: NM_000215.4(JAK3):c.984+18C>T [Likely benign]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 22
1Fase 13
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 1 medicamento · 5 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Imunodeficiência combinada grave T-B+

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥉Melhor nível de evidência: Relato de caso
Timeline de publicações
9 papers (10 anos)
#1

RAG1 lentiviral gene therapy restores T-cell development of RAG1-SCID patient cells in artificial thymic organoids.

Blood advances2025 Nov 25

Recombination activating gene 1 (RAG1) is essential for variable diversity joining recombination during early T- and B-cell development. Null mutations cause a complete block in receptor rearrangement, resulting in T-B- severe combined immunodeficiency (SCID). Patients with RAG1-SCID require hematopoietic stem cell transplantation for survival. Our phase I/II clinical trial (NCT04797260) is currently evaluating lentiviral RAG1 gene addition in autologous hematopoietic stem and progenitor cells (HSPCs). However, studying early human T-cell development is challenging due to limited access to thymic tissue. The artificial thymic organoid (ATO) system offers a promising in vitro model to study human T-cell differentiation. Here, we show that ATO cultures efficiently support T-cell development from healthy donor HSPCs derived from umbilical cord blood or mobilized peripheral blood, yielding not only αβ but also γδ T cells with a polyclonal T-cell receptor (TCR) repertoire. In contrast, noncorrected RAG1-deficient HSPCs from 3 RAG1-SCID patients show a developmental arrest before or at the aberrant CD4+CD8dim double-positive stage, characterized by minimal or absent CD1a upregulation and CD7 downregulation, absence of TCRβ rearrangement, and only partial TCRγ and TCRδ rearrangement. Lentiviral RAG1 gene addition using the clinical vector rescues T-cell development in these patient-derived HSPCs and restores TCR repertoire diversity. These findings highlight the ATO system as a valuable model for dissecting human T-cell development and for the preclinical development and evaluation of gene therapy.

#2

AK2-Deficient Mice Recapitulate Impaired Lymphopoiesis of Reticular Dysgenesis Patients, but Also Lack Erythropoiesis.

European journal of immunology2025 Jul

Reticular dysgenesis (RD) is a rare genetic disorder caused by mutations in the adenylate kinase 2 (AK2) gene. It is characterized by a T-B- severe combined immunodeficiency, agranulocytosis, and sensorineural deafness. We established and characterized a haematopoiesis-specific conditional Ak2-knockout mouse model to provide a model system to study the molecular pathophysiology of RD. As expected from the human phenotype of RD, haematopoiesis-specific AK2-deficient embryos had a small, atrophic thymus consisting mainly of epithelial cells. No recognizable T-cell component was observed, but B-cell lineage precursor cells were present in the foetal liver. The effects of AK2 deficiency on myelopoiesis were less severe in mice than in humans. The absolute numbers of monocytes, macrophages, granulocytes and megakaryocytes in foetal liver as well as colony-forming precursors were not reduced. In contrast to humans, haematopoiesis-specific Ak2-knockout mice exhibit embryonic lethality between E13 and E15 due to severe anaemia caused by an early block in definitive erythropoiesis. Murine erythroid progenitors mainly express AK2 and only low levels of functionally related kinases, which are unable to compensate for AK2 deficiency, in contrast to human erythroid progenitors.

#3

IL-7 receptor signaling drives human B-cell progenitor differentiation and expansion.

Blood2023 Sep 28

Although absence of interleukin-7 (IL-7) signaling completely abrogates T and B lymphopoiesis in mice, patients with severe combined immunodeficiency caused by mutations in the IL-7 receptor α chain (IL-7Rα) still generate peripheral blood B cells. Consequently, human B lymphopoiesis has been thought to be independent of IL-7 signaling. Using flow cytometric analysis and single-cell RNA sequencing of bone marrow samples from healthy controls and patients who are IL-7Rα deficient, in combination with in vitro modeling of human B-cell differentiation, we demonstrate that IL-7R signaling plays a crucial role in human B lymphopoiesis. IL-7 drives proliferation and expansion of early B-cell progenitors but not of pre-BII large cells and has a limited role in the prevention of cell death. Furthermore, IL-7 guides cell fate decisions by enhancing the expression of BACH2, EBF1, and PAX5, which jointly orchestrate the specification and commitment of early B-cell progenitors. In line with this observation, early B-cell progenitors of patients with IL-7Rα deficiency still expressed myeloid-specific genes. Collectively, our results unveil a previously unknown role for IL-7 signaling in promoting the B-lymphoid fate and expanding early human B-cell progenitors while defining important differences between mice and humans. Our results have implications for hematopoietic stem cell transplantation strategies in patients with T- B+ severe combined immunodeficiency and provide insights into the role of IL-7R signaling in leukemogenesis.

#4

HyperIgE in hypomorphic recombination-activating gene defects.

Current opinion in immunology2023 Feb

Increased immunogloblulin-E (IgE) levels associated with eosinophilia represent a common finding observed in Omenn syndrome, a severe immunodeficiency caused by decreased V(D)J recombination, leading to restricted T- and B-cell receptor repertoire. V(D)J recombination is initiated by the lymphoid-restricted recombination-activating gene (RAG) recombinases. The lack of RAG proteins causes a block in lymphocyte differentiation, resulting in T-B- severe combined immunodeficiency. Conversely, hypomorphic mutations allow the generation of few T and B cells, leading to a spectrum of immunological phenotypes, in which immunodeficiency associates to inflammation, immune dysregulation, and autoimmunity. Elevated IgE levels are frequently observed in hypomorphic RAG patients. Here, we describe the role of RAG genes in lymphocyte differentiation and maintenance of immune tolerance.

#5

Structural analysis of the basal state of the Artemis:DNA-PKcs complex.

Nucleic acids research2022 Jul 22

Artemis nuclease and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) are key components in nonhomologous DNA end joining (NHEJ), the major repair mechanism for double-strand DNA breaks. Artemis activation by DNA-PKcs resolves hairpin DNA ends formed during V(D)J recombination. Artemis deficiency disrupts development of adaptive immunity and leads to radiosensitive T- B- severe combined immunodeficiency (RS-SCID). An activated state of Artemis in complex with DNA-PK was solved by cryo-EM recently, which showed Artemis bound to the DNA. Here, we report that the pre-activated form (basal state) of the Artemis:DNA-PKcs complex is stable on an agarose-acrylamide gel system, and suitable for cryo-EM structural analysis. Structures show that the Artemis catalytic domain is dynamically positioned externally to DNA-PKcs prior to ABCDE autophosphorylation and show how both the catalytic and regulatory domains of Artemis interact with the N-HEAT and FAT domains of DNA-PKcs. We define a mutually exclusive binding site for Artemis and XRCC4 on DNA-PKcs and show that an XRCC4 peptide disrupts the Artemis:DNA-PKcs complex. All of the findings are useful in explaining how a hypomorphic L3062R missense mutation of DNA-PKcs could lead to insufficient Artemis activation, hence RS-SCID. Our results provide various target site candidates to design disruptors for Artemis:DNA-PKcs complex formation.

Publicações recentes

Ver todas no PubMed

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Imunodeficiência combinada grave T-B+.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Imunodeficiência combinada grave T-B+

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. RAG1 lentiviral gene therapy restores T-cell development of RAG1-SCID patient cells in artificial thymic organoids.
    Blood advances· 2025· PMID 40829114mais citado
  2. AK2-Deficient Mice Recapitulate Impaired Lymphopoiesis of Reticular Dysgenesis Patients, but Also Lack Erythropoiesis.
    European journal of immunology· 2025· PMID 40654267mais citado
  3. IL-7 receptor signaling drives human B-cell progenitor differentiation and expansion.
    Blood· 2023· PMID 37369082mais citado
  4. HyperIgE in hypomorphic recombination-activating gene defects.
    Current opinion in immunology· 2023· PMID 36529093mais citado
  5. Structural analysis of the basal state of the Artemis:DNA-PKcs complex.
    Nucleic acids research· 2022· PMID 35801871mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:317416(Orphanet)
  2. MONDO:0044200(MONDO)
  3. GARD:21405(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55787980(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Imunodeficiência combinada grave T-B+
Compêndio · Raras BR

Imunodeficiência combinada grave T-B+

ORPHA:317416 · MONDO:0044200
🇧🇷 Brasil SUS
Triagem
TREC (T-cell Receptor Excision Circles)
PNTN
Fase 4
Incidência BR
1:50.000
Geral
CID-10
D81.2 · Imunodeficiência combinada grave [SCID] com números baixos ou normais de células B
CID-11
Medicamentos
1 registrados
MedGen
UMLS
C5679894
EuropePMC
Wikidata
Papers 10a
Evidência
🥉 Relato de caso
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades